Prevention & Lipids
Lipid management
Cholesterol treatment and ASCVD risk reduction
Emerging pathwayAlso known as: cholesterol, dyslipidemia, lipid lowering
3,220
Clinical questions
121
Evidence-backed
82
Claims analyzed
Prevention & Lipids
Cholesterol treatment and ASCVD risk reduction
Synthesized from 121 evidence-backed clinical questions linked to this topic — 8 supporting the intervention, 4 against the intervention, 3 still contested.
Does rbd5044 vs placebo improve outcomes in Dyslipidemias?
Low Certainty+ Favors benefitrbd5044 vs placebo
12 studies (611,464 patients) provide low-certainty evidence for benefit of rbd5044 for the outcome in Dyslipidemias.
Does statin vs placebo improve outcomes in Hypercholesterolemia?
Low Certainty+ Favors benefitstatin vs placebo
3 studies (197,856 patients) provide low-certainty evidence for benefit of statin for the outcome in Hypercholesterolemia.
Does statin vs placebo improve outcomes in Hypercholesterolemia, Familial?
Low Certainty− Favors harmstatin vs placebo · Myocardial Infarction Hospitalization
12 studies (23,719 patients) provide low-certainty evidence against benefit of statin for Myocardial Infarction Hospitalization in Hypercholesterolemia, Familial.
Does angiotensin-converting-enzyme inhibitors vs angiotensin ii receptor blockers improve outcomes in Acute Inferior Myocardial Infarction?
Low Certainty− Favors harmangiotensin-converting-enzyme inhibitors vs angiotensin ii receptor blockers
4 studies (15,351 patients) provide low-certainty evidence against benefit of angiotensin-converting-enzyme inhibitors for the outcome in Acute Inferior Myocardial Infarction.
Does statin vs integrase inhibitor improve outcomes in HIV?
Low Certainty− Favors harmstatin vs integrase inhibitor · Myocardial Infarction Hospitalization
2 studies (2,296 patients) provide low-certainty evidence against benefit of statin for Myocardial Infarction Hospitalization in HIV.
Does lipid lowering therapy vs placebo improve outcomes in CVD 112?
Low Certainty+ Favors benefitlipid lowering therapy vs placebo
2 studies (1,936 patients) provide low-certainty evidence for benefit of lipid lowering therapy for the outcome in CVD 112.
Does inclisiran vs placebo improve outcomes in Dyslipidemias?
Insufficient~ Mixed resultsinclisiran vs placebo
5 studies (75 patients) provide insufficient evidence with mixed findings regarding inclisiran for the outcome in Dyslipidemias.
Does Cholesterol-modulating medications including statins (e.g., simvastatin) and ezetimibe vs placebo improve outcomes in Patients with muscular dystrophies (including LGMDR28, Duchenne muscular dystrophy, Becker, myotonic dystrophy, and LGMD) and preclinical models (mdx and dysferlin-deficient mice)?
Insufficient~ Mixed resultsCholesterol-modulating medications including statins (e.g., simvastatin) and ezetimibe vs placebo
Emerging evidence with 82 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does evinacumab vs placebo improve outcomes in Homozygous Familial Hypercholesterolemia?
Low Certainty+ Favors benefitevinacumab vs placebo · Myocardial Infarction Hospitalization
Does statin vs placebo improve outcomes in Hypercholesterolemia, Familial?
Low Certainty− Favors harmstatin vs placebo · Myocardial Infarction Hospitalization
Cardiovascular Risk in Young Persons: Secondary or Primordial Prevention?
Annals of Internal Medicine — Berenson G — Aug 2010
Regional fat mass by DXA: High leg fat mass attenuates the relative risk of insulin resistance and dyslipidaemia in obese but not in overweight postmenopausal women
Scandinavian Journal of Clinical and Laboratory Investigation — Aasen G — Jan 2008
Predicting the 10-year incidence of dyslipidemia based on novel anthropometric indices, using data mining
Lipids in Health and Disease — Takhttavous A — Jan 2024
Burden of comorbidities in heart failure patients in Türkiye
TURKISH JOURNAL OF MEDICAL SCIENCES — Çavuşoğlu Y — Jan 2024
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70)
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Lipid management (also known as cholesterol, dyslipidemia, lipid lowering). Cholesterol treatment and ASCVD risk reduction
Synapse tracks 3 specific clinical questions in Lipid management, each synthesized independently from its own trial evidence. They include: "Does evinacumab vs placebo improve outcomes in Homozygous Familial Hypercholesterolemia?"; "Does statin vs placebo improve outcomes in Hypercholesterolemia, Familial?"; "Does statin vs integrase inhibitor improve outcomes in HIV?".
As of 2026-08-14, the scientific consensus on Lipid management is emerging. Emerging evidence with 82 primary claims Based on 82 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/lipid-management.
Deterministic synthesis from Synapse's enriched corpus — 102 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Lipid management paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Lipid management papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
3 studies (0 patients) provide insufficient evidence with mixed findings regarding Cholesterol-modulating medications including statins (e.g., simvastatin) and ezetimibe for the outcome in Patients with muscular dystrophies (including LGMDR28, Duchenne muscular dystrophy, Becker, myotonic dystrophy, and LGMD) and preclinical models (mdx and dysferlin-deficient mice).
American Journal of Cardiovascular Drugs — Sugawara M — Dec 2018